Filtered By:
Infectious Disease: COVID-19
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1386 results found since Jan 2013.
Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1
CONCLUSION: In HLA-A2 positive patients with advanced NSCLC and secondary resistance to immunotherapy, OSE2101 increased survival with better safety compared to chemotherapy. Further evaluation in this population is warranted.PMID:37704166 | DOI:10.1016/j.annonc.2023.07.006
Source: Ann Oncol - September 13, 2023 Category: Cancer & Oncology Authors: B Besse E Felip R Garcia Campelo M Cobo C Mascaux A Madroszyk F Cappuzzo W Hilgers G Romano F Denis S Viteri D Debieuvre D Galetta E Baldini None M Razaq G Robinet M Maio A Delmonte B Roch P Masson W Schuette A Zer J Remon D Costantini B Vasseur R Dziadzi Source Type: research
Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial
CONCLUSIONS: In this double-blind placebo-controlled phase III trial, melatonin did not prevent or significantly improve fatigue and other symptoms in patients with early stage breast cancer undergoing RT. The analysis, showing little evidence of an effect, at mid-recruitment, assured early termination of the trial.PMID:37699115 | DOI:10.1093/oncolo/oyad250
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Nitai D Mukhopadhyay Adam Khorasanchi Sudeep Pandey Srinidhi Nemani Gwendolyn Parker Xiaoyan Deng Douglas W Arthur Alfredo Urdaneta Egidio Del Fabbro Source Type: research
The Impact of COVID19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center In Italy
CONCLUSIONS: There was no evidence for major changes in the management of patients with EBC during 2019-2021 and no treatment delays were observed. Our findings suggest that more women presented with palpable nodules at diagnosis, but the stage distribution did not change over time. Validation on a larger cohort of patients is warranted to robustly assess the impact of the COVID19 pandemic on treatment practices for patients with EBC.PMID:37699107 | DOI:10.1093/oncolo/oyad255
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Fabio Girardi Sabrina Marini Francesca Porra Sonia Carpentieri Alberto Marchet Tania Saibene Marcello Lo Mele Tommaso Giarratano Carlo Alberto Giorgi Eleonora Mioranza Cristina Falci Giovanni Faggioni Francesca Caumo Gaia Griguolo Maria Vittoria Dieci Val Source Type: research
Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial
CONCLUSIONS: In this double-blind placebo-controlled phase III trial, melatonin did not prevent or significantly improve fatigue and other symptoms in patients with early stage breast cancer undergoing RT. The analysis, showing little evidence of an effect, at mid-recruitment, assured early termination of the trial.PMID:37699115 | DOI:10.1093/oncolo/oyad250
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Nitai D Mukhopadhyay Adam Khorasanchi Sudeep Pandey Srinidhi Nemani Gwendolyn Parker Xiaoyan Deng Douglas W Arthur Alfredo Urdaneta Egidio Del Fabbro Source Type: research
The Impact of COVID19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center In Italy
CONCLUSIONS: There was no evidence for major changes in the management of patients with EBC during 2019-2021 and no treatment delays were observed. Our findings suggest that more women presented with palpable nodules at diagnosis, but the stage distribution did not change over time. Validation on a larger cohort of patients is warranted to robustly assess the impact of the COVID19 pandemic on treatment practices for patients with EBC.PMID:37699107 | DOI:10.1093/oncolo/oyad255
Source: The Oncologist - September 12, 2023 Category: Cancer & Oncology Authors: Fabio Girardi Sabrina Marini Francesca Porra Sonia Carpentieri Alberto Marchet Tania Saibene Marcello Lo Mele Tommaso Giarratano Carlo Alberto Giorgi Eleonora Mioranza Cristina Falci Giovanni Faggioni Francesca Caumo Gaia Griguolo Maria Vittoria Dieci Val Source Type: research
Nine-year Follow-up of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma
We report 9-year follow up of a multi-center phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of MCL. The LR doublet is used as induction and maintenance until progression, with optional discontinuation after 3 years. We previously reported an overall response rate in evaluable patients of 92%, with 64% achieving a complete response. At a median follow up of 103 months, 17 (47%) of 36 evaluable patients remain in remission. The 9-year progression-free survival (PFS) and overall survival (OS) were 51% and 66%, respectively. During maintenance, hematologic adverse events (AEs) included asymptomatic grad...
Source: Adv Data - September 8, 2023 Category: Epidemiology Authors: Samuel Yamshon Gui Chen Caitlin Gribbin Paul Christos Bijal D Shah Stephen J Schuster Sonali M Smith Jakub Svoboda Richard R Furman John P Leonard Peter Martin Jia Ruan Source Type: research
Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
CONCLUSIONS AND RELEVANCE: In this cohort study, relative risk of developing VTE was high among patients receiving TOIs and varied by the type of therapy, underlying risk factors, and demographics, such as race and ethnicity. These findings highlight the need for close monitoring and perhaps personalized thromboprophylaxis to prevent morbidity and mortality associated with COVID-19-related thromboembolism in patients with cancer.PMID:37589970 | PMC:PMC10436185 | DOI:10.1001/jamaoncol.2023.2934
Source: Ann Oncol - August 17, 2023 Category: Cancer & Oncology Authors: Shuchi Gulati Chih-Yuan Hsu Surbhi Shah Pankil K Shah Rebecca Zon Susan Alsamarai Joy Awosika Ziad El-Bakouny Babar Bashir Alicia Beeghly Stephanie Berg Daniel de-la-Rosa-Martinez Deborah B Doroshow Pamela C Egan Joshua Fein Daniel B Flora Christopher R F Source Type: research
Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review
Curr Microbiol. 2023 Aug 17;80(10):322. doi: 10.1007/s00284-023-03430-w.ABSTRACTAlthough mucormycosis may have reached an epidemic situation during the COVID-19 pandemic, the term was much more familiar even before the COVID-19 period. The year 2020 showed an outbreak of novel coronavirus (SARS-CoV-2) which affected millions of people all over the world. One of the noticeable complications observed to be associated with this disease is mucormycosis. It is an opportunistic infection caused by members of the Order Mucorales existing worldwide and has been commonly reported as a laboratory contaminant for a long time. However...
Source: Current Microbiology - August 17, 2023 Category: Microbiology Authors: Bharti Sharma Skarma Nonzom Source Type: research
Impact of the COVID-19 Pandemic on Delays to Breast Cancer Surgery: Ripples or Waves?
CONCLUSION: The COVID-19 pandemic was associated with significant DTS for breast cancer but spared time to systemic therapy. Delays disproportionately impacted vulnerable and underserved patient populations. The true clinical effects of these delays may yet be realized for breast cancer patients.PMID:37526751 | DOI:10.1245/s10434-023-13878-6
Source: Ann Oncol - August 1, 2023 Category: Cancer & Oncology Authors: Sophie H Chung Kelsey S Romatoski Gordana Rasic Brendin R Beaulieu-Jones Kelly Kenzik Andrea L Merrill Jennifer F Tseng Michael R Cassidy Teviah E Sachs Source Type: research
Time-Related Vascular Inflammatory Response to COVID-19 Assessed by < sup > 18 < /sup > F-FDG PET/CT in Follow-Up Tumor Patients
CONCLUSION: This work firstly suggested vascular inflammation is elevated in the early post-COVID-19 phase in DLBCL cases compared with prolonged post-COVID-19 phase or controls. Increasing attention should be paid to these patients and the protection of their vascular function and complications in early COVID-19.PMID:37520665 | PMC:PMC10378463 | DOI:10.2147/JIR.S415288
Source: Cell Research - July 31, 2023 Category: Cytology Authors: Runlong Lin Jing Yu Aijuan Tian Xiaomei Wang Xin Yuan Wengui Xu Wenli Xie Source Type: research
Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK
CONCLUSION: This study suggests that changes to radiotherapy and chemotherapy made in response to the COVID-19 pandemic did not significantly affect distant relapse or survival. Changes to radiotherapy, namely increased hypofractionation, led to increased odds of grade ≥3 acute toxicity. These results are important, as hypofractionated treatments can help to reduce hospital attendances in the context of potential future emergency situations.PMID:37507280 | DOI:10.1016/j.clon.2023.07.005
Source: Clinical Lung Cancer - July 28, 2023 Category: Cancer & Oncology Authors: I Fornacon-Wood K Banfill S Ahmad A Britten C Carson N Dorey M Hatton C Hiley K Thippu Jayaprakash A Jegannathen A C Kidd P Koh N Panakis C Peedell A Peters A Pope C Powell C Stilwell B Thomas E Toy K Wicks V Wood S Yahya G Price C Faivre-Finn Source Type: research
Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients
Breast. 2023 Jul 20;71:60-62. doi: 10.1016/j.breast.2023.07.011. Online ahead of print.ABSTRACTWe studied the COVID-19 impact in newly-diagnosed breast cancer (7,349 patients in 2019, and 5,563 in 2020). In 2020 there were two diagnostic drops: -37.2% (March-May), -15.8% (October-December). Early-stage at presentation (76.4% vs. 74.4%, p = 0.0013), conserving surgery (71.0% vs. 67.0%, p < 0.0001), chemotherapy (86.2% vs. 53.4%, p < 0.0001), and radiotherapy (65.7% vs. 42.1%, p < 0.0001) decreased in 2020 compared to 2019. COVID-19 occurred in 250 patients (4.49%). The time-dependent COVID-19 effect was associated ...
Source: Breast - July 27, 2023 Category: Cancer & Oncology Authors: Serena Di Cosimo Silva Ljevar Annalisa Trama Alice Bernasconi Paolo Lasalvia Maria Carmen De Santis Vera Cappelletti Rosalba Miceli Giovanni Apolone Source Type: research
